Zostavax

Zostavax Special Precautions

vaccine, varicella-zoster

Manufacturer:

MSD

Distributor:

Zuellig Pharma
Full Prescribing Info
Special Precautions
The health care provider should question the patient about reactions to a previous dose of any VZV-containing vaccines (see Contraindications).
As with any vaccine, adequate treatment provisions, including epinephrine injection (1:1000), should be available for immediate use should an anaphylactic/anaphylactoid reaction occur.
Deferral of vaccination should be considered in the presence of fever >38.5°C (>101.3°F).
The safety and efficacy of ZOSTAVAX have not been established in adults who are known to be infected with human immunodeficiency virus (HIV), with or without evidence of immunosuppression. A phase II safety and immunogenicity study in HIV-infected adults with conserved immune function has been completed (see Pharmacology: Special Populations under Actions and Side Effects).
As with any vaccine, vaccination with ZOSTAVAX may not result in protection of all vaccine recipients.
Transmission: In clinical trials with ZOSTAVAX, transmission of the vaccine virus has not been reported. However, post-marketing experience with varicella vaccines suggests that transmission of vaccine virus may occur rarely between vaccinees who develop a varicella-like rash and susceptible contacts. Transmission of vaccine virus from varicella vaccine recipients who do not develop a varicella-like rash has also been reported. This is a theoretical risk for vaccination with ZOSTAVAX. The risk of transmitting the attenuated vaccine virus to a susceptible individual should be weighed against the risk of developing natural zoster that could be transmitted to a susceptible individual.
Use in Children: ZOSTAVAX is not recommended for use in this age group.
Use in the Elderly: The mean age of subjects enrolled in the largest (N=38,546) clinical study of ZOSTAVAX was 69 years (range 59-99 years). Of the 19,270 subjects who received ZOSTAVAX, 10,378 were 60-69 years of age, 7,629 were 70-79 years of age and 1,263 were 80 years of age or older. ZOSTAVAX was demonstrated to be generally safe and effective in this population.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in